Icahn School of Medicine at Mount Sinai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Icahn School of Medicine at Mount Sinai sits in the top decile of US sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count).
Icahn School of Medicine at Mount Sinai: 708 sponsored US clinical trials, 163 recruiting.
Icahn School of Medicine at Mount Sinai sponsors 708 registered US clinical trials on ClinicalTrials.gov, 163 of them currently recruiting, and 423 completed. 88 of these trials are in Phase 3-4 (later-stage) and 138 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 7 trials.
Top-decile sponsor footprint
Icahn School of Medicine at Mount Sinai ranks in the top decile of sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
423 of 499 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
708 total, page 1 of 15
Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation
NCT07260916
Evaluation of Muscle Oxygen With MRI
NCT07638384
Tract Closure in PCNL
NCT07668817
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
NCT07059494
Deucravacitinib in the Treatment of Cicatricial Alopecias
NCT07508488
MDMA Assisted Therapy for BN
NCT07542145
Patient Positioning for Treatment of Proximal Ureteral Stones
NCT07601932
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
NCT07487948
Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery
NCT07539623
Paired Non-invasive VNS in Adolescent Cerebral Palsy Rehabilitation
NCT07394608
Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN
NCT07548385
Neutralizing Interleukin (IL)-6
NCT07493317
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
NCT07027124
Vestibular Innovation in Pain 2
NCT07423377
Impact of Morning Light Therapy in IBD
NCT07207200
Alnuctamab for Refractory SLE (LATTE Study)
NCT07219563
Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder
NCT07318480
Point of Care STI Testing
NCT06844045
Innovative Approaches to Hypertension Management in High-Risk Emergency Department Populations
NCT07539597
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
NCT07285057
Virtual Reality (VR) Self-Hypnosis Software
NCT06398847
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
NCT07242638
The Use of Rhythmic Light Therapy in Mild Cognitive Impairment
NCT07318038
Evaluating a Prototype CT Scan for ICH Evacuation
NCT07455201
Study of Cannabidiol and Neuroimaging on Stress
NCT07278505
CaOx Stone Prevention
NCT07225764
Liver Transplant CGM
NCT07216508
Validating CGM for GDM
NCT06858787
Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation
NCT06938412
Multifaceted Intervention to Restore Resilience and Overcome Risk
NCT06988787
Assessment of Music Experiences in Navigating Depression Part 2
NCT07218055
Transcranial Magnetic Stimulation in Misophonia
NCT06960083
ADAPT: Approach to Dance for Autism
NCT07216768
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
NCT07058974
Paired Vagus Nerve Stimulation in Mobilization of Patients With Prolonged Disorders of Consciousness
NCT06930716
Interventions for Promoting Kidney Transplant Empowerment
NCT06655857
Pregnancy and Postpartum CGM in GDM
NCT07174245
Memory Support System for Older Chinese Americans With Mild Cognitive Impairment
NCT07142499
Precision Analytic Research Methods in OCD
NCT07011901
Virtual Reality for Pain Control in US-Guided Obstetric Needle Procedures
NCT07094451
Adjunctive Cannabidiol for Recovery From Opioid Study
NCT06940674
Acute Migraine Treatment in the ED With Gepants
NCT06985342
Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis
NCT07039019
Use of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder
NCT06858774
Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen
NCT07141121
A Study of the MIND Diet for Persons With Multiple Sclerosis
NCT06992115
Healing Track Clinical Trial
NCT06641102
SeizEAR Safety Study
NCT07088835
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
NCT06960928
Improving Medication Management in World Trade Center Responders
NCT07022990
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 81 |
| Phase 3 | 21 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Icahn School of Medicine at Mount Sinai pipeline
163 recruiting of 708 indexed (23% open); 423 completed (60%).
Phase mix: 88 late (III/IV) vs 138 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Icahn School of Medicine at Mount Sinai: open-pipeline peers nationwide
Peers matched on 708 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 708 trials (± recruiting share)
- Sanofi · 713 trials · 10% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- University of Miami · 721 trials · 20% recruiting
- The Cleveland Clinic · 688 trials · 14% recruiting
Sponsors near 23% open enrollment (± trial volume)
- Clemson University · 23% recruiting · 13 trials
- Liberating Technologies · 23% recruiting · 13 trials
- Rahul Aggarwal · 23% recruiting · 13 trials
- Sequenom · 23% recruiting · 26 trials
Related
What to do with this Icahn School of Medicine at Mount Sinai page
708 registered trials is a research-attention snapshot, not an endorsement of Icahn School of Medicine at Mount Sinai or any single study.
- 163 of Icahn School of Medicine at Mount Sinai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Icahn School of Medicine at Mount Sinai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Icahn School of Medicine at Mount Sinai pipeline card: 708 registered trials from official public datasets.Report a data error.